IN2014MN01056A - - Google Patents

Info

Publication number
IN2014MN01056A
IN2014MN01056A IN1056MUN2014A IN2014MN01056A IN 2014MN01056 A IN2014MN01056 A IN 2014MN01056A IN 1056MUN2014 A IN1056MUN2014 A IN 1056MUN2014A IN 2014MN01056 A IN2014MN01056 A IN 2014MN01056A
Authority
IN
India
Prior art keywords
antifactor
activity
less
heparin
malaria
Prior art date
Application number
Other languages
English (en)
Inventor
Hans Peter Ekre
Ulf Lindahl
Erik Holmer
Per Olov Eriksson
Anna Leitgeb
Mats Wahlgren
Stefania Tidia
Lino Liverani
Original Assignee
Dilaforette Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dilaforette Ab filed Critical Dilaforette Ab
Publication of IN2014MN01056A publication Critical patent/IN2014MN01056A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1056MUN2014 2011-12-19 2012-12-19 IN2014MN01056A (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/SE2011/051538 WO2013095215A1 (en) 2011-12-19 2011-12-19 Low anticoagulant heparins
PCT/SE2012/051428 WO2013095276A1 (en) 2011-12-19 2012-12-19 Low anticoagulant heparins

Publications (1)

Publication Number Publication Date
IN2014MN01056A true IN2014MN01056A (https=) 2015-05-01

Family

ID=48668926

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1056MUN2014 IN2014MN01056A (https=) 2011-12-19 2012-12-19

Country Status (26)

Country Link
US (2) US9480702B2 (https=)
EP (2) EP2794667B1 (https=)
JP (2) JP6703806B2 (https=)
CN (1) CN104053675B (https=)
AU (1) AU2012354226B2 (https=)
BR (1) BR112014014673B1 (https=)
CA (2) CA2856477C (https=)
CY (2) CY1120197T1 (https=)
DK (2) DK2794667T3 (https=)
ES (2) ES2669055T3 (https=)
HR (2) HRP20180725T1 (https=)
HU (2) HUE037554T2 (https=)
IL (1) IL232903A (https=)
IN (1) IN2014MN01056A (https=)
MX (1) MX358439B (https=)
MY (1) MY170069A (https=)
NO (2) NO2794667T3 (https=)
PH (1) PH12014501387A1 (https=)
PL (2) PL2794666T3 (https=)
PT (2) PT2794666T (https=)
RS (2) RS57214B1 (https=)
SI (2) SI2794666T1 (https=)
SM (2) SMT201800217T1 (https=)
TN (2) TN2014000237A1 (https=)
WO (3) WO2013095215A1 (https=)
ZA (1) ZA201403654B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CN104144950B (zh) 2011-12-19 2017-09-05 迪乐方有限责任公司 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途
GB2515315A (en) 2013-06-19 2014-12-24 Dilafor Ab New Processes
ES2749076T3 (es) * 2014-04-30 2020-03-19 Inst Nat Sante Rech Med DNasa para uso en el tratamiento de crisis vaso-oclusivas
EP2965764A1 (en) * 2014-07-11 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating vaso-occlusive crisis
CN105504097B (zh) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 一种硫酸化肝素寡糖及其制备方法和应用
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
CA3097047A1 (en) * 2018-04-13 2019-10-17 University Of Virginia Patent Foundation Compositions and methods for preparing and using non-immunogenic fast annealing microporous annealed particle hydrogels
CN109481692A (zh) * 2018-11-30 2019-03-19 东南大学 一种青蒿琥酯肝素衍生物及其药物组合物和应用
US20250205392A1 (en) * 2022-03-29 2025-06-26 The Penn State Research Foundation Device and method for accelerating and guiding vascularization
WO2023215594A1 (en) 2022-05-05 2023-11-09 Venture Health Studio, Llc Magnetic power distribution assembly
KR20250019674A (ko) * 2022-06-06 2025-02-10 아이에이치피 테라퓨틱스 인크. 화학적으로 변형된 헤파린
JP2025519467A (ja) * 2022-06-06 2025-06-26 アイエイチピー セラピューティクス インコーポレイテッド 化学的に修飾されたヘパリン
CN115448994B (zh) * 2022-09-28 2023-08-01 山东大学 一种可中和抗凝低分子量肝素及其制备方法和应用
US12059430B2 (en) 2022-09-29 2024-08-13 Adora Animal Health Corporation Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
GB2625581A (en) * 2022-12-21 2024-06-26 Modus Therapeutics Ab New medical use
EP4665360A1 (en) 2023-02-17 2025-12-24 Modus Therapeutics AB New medical use of sevuparin in the treatment of endotoxemia
GB2627263A (en) * 2023-02-17 2024-08-21 Modus Therapeutics Ab New medical use
CN116854838A (zh) * 2023-06-30 2023-10-10 重庆望业药物研究有限公司 低分子多糖及其制备方法与应用
GB202407366D0 (en) * 2024-05-23 2024-07-10 Glycos Biomedical Ltd Preparation of medium molecular weight heparin

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
FR2614026B1 (fr) 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
EP0362810B1 (en) * 1988-10-07 1993-05-05 Hoechst Aktiengesellschaft Antimalarial compositions using quinidine, artemisinine and its derivatives
SE9002550D0 (sv) 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) * 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5250519A (en) * 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
WO1994008595A1 (en) 1992-10-13 1994-04-28 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
EP0735050B1 (en) * 1995-03-31 2002-09-25 Hamilton Civic Hospitals Research Development, Inc. Compositions for inhibiting thrombogenesis
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
AU4572797A (en) 1996-10-15 1998-05-11 Toray Industries, Inc. Cervical canal maturing agent
GB9711443D0 (en) 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
WO1999026984A1 (fr) * 1997-11-20 1999-06-03 Ikuo Yamashina Modification de l'heparine de faible masse moleculaire et remede contre l'ulcere de la peau
US6596705B1 (en) * 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
US6498246B1 (en) 1998-02-26 2002-12-24 Seikagaku Corporation Glycosaminoglycan derivatives and processes for preparing same
US6028061A (en) * 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
WO2000006608A1 (en) * 1998-07-31 2000-02-10 Seikagaku Corporation Novel glycosaminoglycan and drug compositions containing the same
CA2377734A1 (en) * 1999-06-30 2001-01-11 Hamilton Civic Hospitals Research Development, Inc. Heparin compositions that inhibit clot associated coagulation factors
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
DE60138115D1 (de) * 2000-09-12 2009-05-07 Massachusetts Inst Technology Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
EP1542704A1 (en) 2002-04-18 2005-06-22 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
EP1582531A1 (en) * 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
ATE516019T1 (de) * 2004-05-11 2011-07-15 Egalet Ltd Quellbare dosierform mit gellan-gummit
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) * 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
US20080214480A1 (en) 2005-07-22 2008-09-04 Trf Pharma, Inc. Method for Treating Sickle Cell Disease and Sickle Cell Disease Sequalae
ZA200801696B (en) * 2005-07-22 2009-08-26 Univ California Heparin compositions and selection inhibition
CN101495517B (zh) * 2006-05-25 2012-10-10 莫曼塔医药品有限公司 低分子量肝素及其用途
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (es) * 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
WO2009073184A1 (en) 2007-12-03 2009-06-11 Florida State University Research Foundation, Inc. Compositions for inducing labor and associated methods
CA2719666C (en) * 2008-04-04 2016-08-16 Glenn Prestwich Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
AU2009273747A1 (en) * 2008-07-25 2010-01-28 Alphapharm Pty Ltd Atovaquone with a particle size diameter range (D90) of greater than 3 um to about 10 um
AU2010236222B2 (en) 2009-04-16 2015-10-15 Momenta Pharmaceuticals, Inc. Methods of assessing activity of a polysaccharide composition
AU2010268756A1 (en) * 2009-06-30 2012-01-19 The Walter And Eliza Hall Institute Of Medical Research Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CN104144950B (zh) 2011-12-19 2017-09-05 迪乐方有限责任公司 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途
HK1203370A1 (en) 2012-03-26 2015-10-30 迪乐方有限责任公司 Method for treatment of labor arrest
HK1203369A1 (en) 2012-03-26 2015-10-30 迪乐方有限责任公司 Combination treatment comprising sulphated glycosaminoglycans for inducing labor

Also Published As

Publication number Publication date
WO2013095276A1 (en) 2013-06-27
CN104053675B (zh) 2016-10-12
CA2856918A1 (en) 2013-06-27
CA2856477C (en) 2017-06-27
JP2015500387A (ja) 2015-01-05
TN2014000237A1 (en) 2015-09-30
US9480702B2 (en) 2016-11-01
JP2018154848A (ja) 2018-10-04
PT2794666T (pt) 2018-05-09
PL2794667T3 (pl) 2018-09-28
AU2012354226B2 (en) 2017-01-12
MY170069A (en) 2019-07-03
NO2794666T3 (https=) 2018-07-21
EP2794666B1 (en) 2018-02-21
IL232903A0 (en) 2014-07-31
RS57214B1 (sr) 2018-07-31
BR112014014673A8 (pt) 2017-07-04
NO2794667T3 (https=) 2018-07-21
CY1120194T1 (el) 2018-12-12
CY1120197T1 (el) 2018-12-12
MX358439B (es) 2018-08-21
WO2013095215A1 (en) 2013-06-27
CA2856918C (en) 2017-07-04
EP2794666A1 (en) 2014-10-29
SMT201800218T1 (it) 2018-05-02
BR112014014673A2 (pt) 2017-06-13
HRP20180725T1 (hr) 2018-06-29
PH12014501387B1 (en) 2014-09-22
EP2794667A1 (en) 2014-10-29
SI2794667T1 (en) 2018-06-29
PL2794666T3 (pl) 2018-08-31
JP6703806B2 (ja) 2020-06-03
US20150031638A1 (en) 2015-01-29
AU2012354226A1 (en) 2014-06-05
RS57213B1 (sr) 2018-07-31
DK2794667T3 (en) 2018-04-23
CA2856477A1 (en) 2013-06-27
HUE037554T2 (hu) 2018-09-28
TN2014000236A1 (en) 2015-09-30
HK1200471A1 (en) 2015-08-07
PH12014501387A1 (en) 2014-09-22
MX2014006956A (es) 2014-10-17
EP2794666A4 (en) 2015-07-22
ZA201403654B (en) 2017-08-30
ES2669055T3 (es) 2018-05-23
DK2794666T3 (en) 2018-04-23
US20140364369A1 (en) 2014-12-11
WO2013095277A1 (en) 2013-06-27
HK1199893A1 (en) 2015-07-24
EP2794667B1 (en) 2018-02-21
ES2668273T3 (es) 2018-05-17
BR112014014673B1 (pt) 2021-02-17
EP2794667A4 (en) 2015-07-22
IL232903A (en) 2017-02-28
CN104053675A (zh) 2014-09-17
US9480701B2 (en) 2016-11-01
PT2794667T (pt) 2018-05-16
SI2794666T1 (en) 2018-06-29
SMT201800217T1 (it) 2018-05-02
HUE037555T2 (hu) 2018-09-28
NZ625096A (en) 2016-07-29
HRP20180726T1 (hr) 2018-06-15

Similar Documents

Publication Publication Date Title
IN2014MN01056A (https=)
DK2794665T3 (da) Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf
IN2014DN09782A (https=)
PH12013500919B1 (en) Vasoprotective and cardioprotective antidiabetic therapy
MY169328A (en) Compositions for the treatment of dry eye
EA201290497A1 (ru) Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
WO2013106385A3 (en) System and methods for determining tissue elasticity
MX2019005130A (es) Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente.
MX2015007410A (es) Membrana de hidrogel para prevencion de la adhesion.
PH12013502149A1 (en) Modified acid alpha glucosidase with accelerated processing
MY151104A (en) Novel use
MX364220B (es) Metodos de tratamientos de fibrosis.
NZ631279A (en) Method for treatment of labor arrest
NZ703260A (en) Polysaccharide compositions and methods of use
MX365289B (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alfa-2c.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
TN2012000581A1 (en) Piperidinyl compound as a modulator of chemokine receptor activity
MX2019009711A (es) Mejoras en o con respecto a compuestos organicos.
TR201909158T4 (tr) siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.
WO2014127232A3 (en) Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy
MX371198B (es) Terapia antidiabetica vasoprotectora y cardioprotectora.
WO2016027160A3 (en) Nasal composition comprising mixture of hyaluronic acids and saline solution
TH154800A (th) เฮพารินที่ต้านการแข็งตัวของเลือดได้ต่ำ (Low Anticoagulant Heparins)
MX2012006966A (es) Tratamiento de padecimientos mediados por citocina.